Clinical Research Directory
Browse clinical research sites, groups, and studies.
66 clinical studies listed.
Filters:
Tundra lists 66 Ovarian Carcinoma clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT06995898
The Vanguard Study: Testing a New Way to Screen for Cancer
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).
Gender: All
Ages: 45 Years - 75 Years
Updated: 2026-11-20
14 states
NCT06677190
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, including but not limited to, ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, or endometriosis-related cancer. The name of the study drug involved in this study is: \- Belzutifan (a type of Hypoxia-Inducible Factor-2 alpha (HIF-2a) inhibitor)
Gender: FEMALE
Ages: 18 Years - Any
Updated: 2026-11-19
1 state
NCT02345265
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
This phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement (recurrent). Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender: FEMALE
Ages: 18 Years - Any
Updated: 2026-11-18
10 states
NCT04314401
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.
Gender: All
Ages: 13 Years - Any
Updated: 2026-11-18
30 states
NCT01696994
Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)
This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).
Gender: FEMALE
Ages: 55 Years - 74 Years
Updated: 2026-11-18
1 state
NCT01366144
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with paclitaxel and carboplatin may kill more tumor cells.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-18
12 states
NCT05927818
Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer
The primary goal of this prospective study is to define the efficacy of the sentinel lymph node biopsy (SLNB) procedure by comparing it to the results obtained from systematic lymphadenectomy, each performed in participants with a suspicious adnexal mass for early-stage ovarian cancer.
Gender: FEMALE
Ages: 18 Years - 90 Years
Updated: 2026-11-18
1 state
NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal squamous cell carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, breast, and cervical second-line/third-line (cervical 2L/3L) cancer.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-17
12 states
NCT04981119
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-17
11 states
NCT05180851
A Clinical Study of Recombinant Oncolytic Adenovirus L-IFN Injection With Multiple Administration Routes in Relapsed/Refractory Solid Tumors
This is an open-label, dose-escalation study evaluating the safety and tolerability of Recombinant Oncolytic Adenovirus L-IFN Injection (YSCH-01) administered via different routes, including intratumoral injection and aerosol therapy, in patients with advanced solid tumors. The purpose of this study is to assess the safety and tolerability of Recombinant L-IFN adenovirus injectionand to determine the recommended phase 1 dose for further study. The study will also evaluate antitumor activity, objective response rate, pharmacokinetics and virus shedding of Recombinant L-IFN adenovirus injection
Gender: All
Ages: 18 Years - 75 Years
Updated: 2026-11-16
1 state
NCT06885424
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-16
4 states
NCT07940062
Co-Existent Endometrial and Ovarian Carcinoma: Molecular Stratification for Pathologic Reporting and Clinical Management
Patients with co-existent endometrial and ovarian carcinomas (CEOCs) are treated inconsistently due to a lack of clear standardized treatment guidelines. Patients may be over-treated and face substantial physical side effects and financial challenges due to additional chemotherapy or radiation appointments. Previous retrospective research has shown that using specific molecular and pathologic criteria to stratify patients' CEOC tumours can identify patients at very low risk of cancer recurrence (during an average 6 years of follow-up), with no demonstrated benefit of additional treatment after surgery. The goal of this study is to determine the safety of receiving no additional treatment (i.e. no chemotherapy or radiation) after surgery in patients diagnosed with a co-existent endometrial and ovarian cancer (CEOC) meeting highly selective molecular and pathologic criteria. Patients with CEOC who also meet predefined molecular criteria (low risk POLEmut, ER+NSMP, or MSH2/MSH6/PMS2 loss without MLH1 promoter hypermethylation in the endometrium and ovary) and pathology criteria (see schema) are eligible to participate. Patients may choose, or be directed by their physician to receive no additional treatment after surgery or to receive additional treatment. To determine the safety of this approach, the study team will evaluate pelvic recurrence (primary) rate, as well as vaginal and distant recurrences, recurrence-free and disease- specific, and overall survival, quality of life, and health economic metrics among patients who do, and do not receive additional treatment after surgery. Study design is pragmatic, designed to match recommended standard of care as closely as possible. Patients will have regular follow-up appointments with their oncologist every 4 months for 3 years as part of their medical care. During this time, patients will complete quality of life surveys at baseline, 4, 12, 24, and 36 months. Baseline imaging, and imaging at completion of 3-years are required.
Gender: FEMALE
Ages: 18 Years - Any
Updated: 2026-11-16
1 state
NCT06964009
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian and endometrial cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)
Gender: FEMALE
Ages: 18 Years - Any
Updated: 2026-11-13
1 state
NCT04905082
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
This clinical trial studies the effectiveness of a web-based cancer education tool called Helping Oncology Patients Explore Genomics (HOPE-Genomics) in improving patient knowledge of personal genomic testing results and cancer and genomics in general. HOPE-Genomics is a web-based education tool that teaches cancer/leukemia patients, and patients who may be at high-risk for developing cancer, about genomic testing and provide patients with information about their own genomic test results. The HOPE-Genomics tool may improve patient's genomic knowledge and quality of patient-centered care. In addition, it may also improve education and care quality for future patients.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-12
1 state
NCT02465060
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-12
51 states
NCT05194735
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors. The study ended during Phase I Arm A after 8 subjects were treated. Arm B and Phase II were not initiated, and the maximum tolerated dose or recommended Phase II dose was not determined.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-09
1 state
NCT06580314
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-09
56 states
NCT04251052
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
Gender: FEMALE
Ages: 35 Years - 50 Years
Updated: 2026-11-06
52 states
NCT06295965
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.
Gender: All
Updated: 2026-11-06
1 state
NCT06586957
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Monotherapy Expansion phase of the study (Part 2) is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D). The goal of the Combination Dose Escalation phase (Part 3) of the study is to identify the RDE of NKT3964 in combination with chemotherapy in adult subjects with advanced/metastatic endometrial cancer. The goal of the Combination Expansion phase of the study (Part 4) is to evaluate the preliminary anti-tumor activity of NKT3964 in combination with chemotherapy at the RDE based on ORR.
Gender: All
Ages: 19 Years - Any
Updated: 2026-11-05
14 states
NCT07495124
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
This phase II trial studies how well giving the insulin-like growth factor binding protein 2 \[pUMVC3-hIGFBP-2 multi-epitope plasmid deoxyribonucleic acid (DNA) (IGFBP-2)\] vaccine after one dose of carboplatin works to stop ovarian cancer from growing, spreading, or getting worse (progressing) in patients whose cancer recurrence is detected only in the blood (serologic detection) following treatment with platinum chemotherapy. IGFBP-2 is a protein found in ovarian cancer cells. The IGFBP-2 vaccine may help the body build an effective immune response to kill tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It has been shown to activate parts of the immune system that may act against tumors. Giving the IGFBP-2 vaccine after a single dose of carboplatin may be an effective way to stop ovarian cancer from progressing in patients with serologic detection following treatment with platinum chemotherapy.
Gender: FEMALE
Ages: 18 Years - Any
Updated: 2026-11-02
1 state
NCT07118176
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues (the biodistribution) in patients with solid tumors or hematologic (blood) cancers. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi-46. Because some cancers take up 68Ga-FAPi-46, it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in a patient's body. Combining a PET scan with a CT scan can help make the image easier to interpret. PET/CT scans are hybrid scanners that combine both modalities into a single scan during the same examination.
Gender: All
Ages: 18 Years - Any
Updated: 2026-10-20
1 state
NCT02412124
Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers
This pilot clinical trial studies a peer-to-peer support program in improving quality of life outcomes in patients with gynecologic cancer and their caregivers. Peer-to-peer support and mentoring may help improve quality of life and reduce symptoms of distress in gynecologic cancer patients and their families.
Gender: FEMALE
Ages: 19 Years - Any
Updated: 2026-10-20
1 state
NCT07741968
A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
This clinical trial studies whether an intervention supported by technology (blended e-health intervention) works to improve fear of progression (FOP) in women with gynecologic or breast cancer. FOP is the fear patients experience from the possibility that their cancer could grow, spread, or get worse. Managing FOP is a leading unmet concern of cancer patients. High levels of FOP are associated with distress, depression, and increased health care costs, despite this, access to resources to address FOP remain limited. The blended e-health intervention in this trial offers remote group sessions along with online sessions to help patients access the information. Session content incorporates values-based goal setting and skills practices to manage unhelpful beliefs about worry and promote helpful coping behaviors. The sessions may help patients recognize unhelpful thoughts and behaviors which reinforce worry. A blended e-health intervention may be an effective way to improve FOP in women with gynecologic or breast cancer.
Gender: FEMALE
Ages: 18 Years - Any
Updated: 2026-10-16
1 state